Elvire Pons-Tostivint

9PUBLICATIONS
47CO-AUTHORS
Gene expression (incl. microarray and other genome-wide approaches)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Mar 13, 2025
Absolute Quantification of Nucleotide Variants in Cell-Free DNA via Quantitative NGS: Clinical Application in Non-Small Cell Lung Cancer Patients.

Guillaume Herbreteau, Marie Marcq, Chloé Sauzay

|Jan 06, 2025
Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study.

Jacob Sands, Myung-Ju Ahn, Aaron Lisberg

|Sep 09, 2024
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.

Myung-Ju Ahn, Kentaro Tanaka, Luis Paz-Ares

|Jun 02, 2024
Impact of PD-L1 Expression on the Overall Survival of Caucasian Patients with Advanced EGFR-Mutant NSCLC Treated with Frontline Osimertinib.

Thomas Papazyan, Marc G Denis, Christine Sagan

|Sep 11, 2023
Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.

Koichi Goto, Yasushi Goto, Toshio Kubo

|Oct 27, 2022
Treatments for Non-Small-Cell Lung Cancer: The Multiple Options for Precision Medicine.

Elvire Pons-Tostivint, Jaafar Bennouna

Pageof 2

Frequent Collaborators

3 joint publications

Myung-Ju Ahn

3 joint publications

Marc Guillaume Denis

3 joint publications

Maurice Pérol

2 joint publications

Jacob Sands